IceCure Secures 180-Day Nasdaq Extension to Meet $1.00 Bid Requirement
IceCure Medical received a 180-day extension from Nasdaq until November 9, 2026 to regain compliance with the $1.00 minimum bid price rule. The company may implement a reverse share split if its ordinary shares fail to trade at $1.00 for ten consecutive business days.
1. Nasdaq Extension Details
IceCure Medical has been granted an additional 180-day compliance period by Nasdaq, extending the deadline to November 9, 2026 to meet the minimum $1.00 bid price rule. This extension follows a notification dated November 12, 2025 and a failed first compliance period that ended on May 11, 2026.
2. Compliance Roadmap and Risks
To regain compliance, IceCure must achieve a closing bid price of at least $1.00 per share for ten consecutive business days; Nasdaq may require up to 20 days of sustained compliance before confirming long-term status. Failure to meet the requirement could result in delisting or compel the company to execute a reverse share split to elevate its share price.